Download
s12325-022-02059-8.pdf 463,19KB
WeightNameValue
1000 Titel
  • Understanding the Patient Experience of Hunger and Improved Quality of Life with Setmelanotide Treatment in POMC and LEPR Deficiencies
1000 Autor/in
  1. Wabitsch, Martin |
  2. Fehnel, Sheri |
  3. Mallya, Usha G. |
  4. Sluga-O’Callaghan, Martina |
  5. Richardson, David |
  6. Price, Mark |
  7. Kühnen, Peter |
1000 Verlag Springer Healthcare
1000 Erscheinungsjahr 2022
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2022-02-22
1000 Erschienen in
1000 Quellenangabe
  • 39(4):1772-1783
1000 Copyrightjahr
  • 2022
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s12325-022-02059-8 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8862005/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Introduction!#!In patients with pro-opiomelanocortin (POMC) or leptin receptor (LEPR) deficiency, managing obesity and hyperphagia can be burdensome for patients and caretakers. The impacts on health-related quality of life are under-recognized and are not well characterized.!##!Methods!#!We conducted in-depth qualitative interviews in patients with POMC (n = 3) and LEPR (n = 2) deficiencies participating in an ongoing open-label extension of phase 3 clinical trials with the melanocortin receptor 4 agonist setmelanotide to describe the patient experience of hyperphagia and characterize changes following treatment with setmelanotide.!##!Results!#!Prior to setmelanotide treatment, all five patients described abnormal sensations of hunger with none indicating feeling satiated after meals and also reported that the burden of hyperphagia impacted their families, emotions, and work and/or school functioning. Following setmelanotide treatment, all five patients reported consistent reductions in hunger and weight, decreased eating, and feeling satiated after meals in addition to substantial improvements in each area of functioning they had previously reported. All five patients indicated they were very satisfied with the impact of setmelanotide on their quality of life and would be upset if treatment was discontinued.!##!Conclusions!#!In patients with POMC or LEPR deficiency, hyperphagia and the inability to feel satiety negatively impacted quality of life. By reducing hunger and improving satiety, setmelanotide facilitated important changes in the lives of these patients. This qualitative research study suggests that the impact of setmelanotide goes beyond favorable clinical changes (e.g., weight and hunger) to also include quality of life improvements that are highly meaningful to patients.
1000 Sacherschließung
lokal Pro-Opiomelanocortin [MeSH]
lokal Pro-Opiomelanocortin
lokal Disease Burden
lokal Humans [MeSH]
lokal Patient Outcome Assessment [MeSH]
lokal Hyperphagia/drug therapy [MeSH]
lokal Melanocortin Receptor
lokal Medical and Health Sciences
lokal Hunger [MeSH]
lokal Quality of Life [MeSH]
lokal Hyperphagia
lokal Original Research
lokal Leptin Receptor
lokal Rare Genetic Diseases of Obesity
lokal alpha-MSH/analogs
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/V2FiaXRzY2gsIE1hcnRpbg==|https://frl.publisso.de/adhoc/uri/RmVobmVsLCBTaGVyaQ==|https://frl.publisso.de/adhoc/uri/TWFsbHlhLCBVc2hhIEcu|https://frl.publisso.de/adhoc/uri/U2x1Z2EtT_KAmUNhbGxhZ2hhbiwgTWFydGluYQ==|https://frl.publisso.de/adhoc/uri/UmljaGFyZHNvbiwgRGF2aWQ=|https://frl.publisso.de/adhoc/uri/UHJpY2UsIE1hcms=|https://orcid.org/0000-0003-0211-176X
1000 Hinweis
  • DeepGreen-ID: 2245d8d7f59f48beb46d26b3e99c4586 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Förderer
  1. Rhythm Pharmaceuticals, Inc |
  2. Charité – Universitätsmedizin Berlin |
1000 Fördernummer
  1. -
  2. -
1000 Förderprogramm
  1. -
  2. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Rhythm Pharmaceuticals, Inc |
    1000 Förderprogramm -
    1000 Fördernummer -
  2. 1000 joinedFunding-child
    1000 Förderer Charité – Universitätsmedizin Berlin |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6486156.rdf
1000 Erstellt am 2024-10-03T00:18:48.601+0200
1000 Erstellt von 322
1000 beschreibt frl:6486156
1000 Zuletzt bearbeitet 2025-09-14T20:56:04.217+0200
1000 Objekt bearb. Sun Sep 14 20:56:04 CEST 2025
1000 Vgl. frl:6486156
1000 Oai Id
  1. oai:frl.publisso.de:frl:6486156 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source